Tiko Traders Technical Vies APHA, ACB Weed

Aphria Receives Health Canada License Amendment, Approving Fully Expanded Production at Aphria One  Annual cannabis production capacity at Aphria One increases to 110,000 kg and 115,000 kgs for all licensed facilities Aphria One among leaders in the industry with automation technology for improved efficiency and quality Leamington, Ontario – March 04, 2019 – Aphria Inc. (“Aphria” or the “Company”) (TSX:APHA and NYSE:APHA) today announced that Health Canada has granted the Company its license amendment, permitting Aphria to commence production in an additional 800,000 square feet of facilities at its Aphria One location, as part of the Company’s completed Part IV and Part V expansions. “This is a major milestone for Aphria on its path to becoming a leading global cannabis producer, as well as a positive development greatly anticipated by the Canadian cannabis industry,” said Irwin D. Simon, Interim CEO of Aphria. “Aphria’s progress expanding production and automation is essential to our strategy of securing scale and long-term advantages that enable the evolution of the cannabis industry through product and brand innovation. With Aphria One, we now have the ability to expand our production capacity by over three times.” Simon concluded, “We are ready to hit the ground running and look forward to alleviating industry-wide supply constraints with our greatly expanded production capacity and sophisticated, proprietary automation technology that will ensure Aphria remains at the forefront of cannabis cultivation and innovation. In anticipation of Health Canada’s approval, we had allocated a portion of our previously approved capacity to mother and vegetative plants that will be used as the initial growing crops in Part IV and Part V. As a result of these measures, growing operations in the expanded facilities are expected to commence without delay. By this Friday, we will move swiftly to establish nearly 22,000 plants in the Part IV and Part V expansion, with an additional 12,000 plants added each week thereafter until we reach full crop rotation.” Industry-Leading Automation The completed Part IV & Part V expansions at Aphria One bring industrial-scale horticulture production technology to cannabis cultivation. While critical phases such as initial cuttings, trimming and pruning mature plants will be performed by hand, the in-house designed technology will automate key steps, including: Transplanting cuttings Transporting plants through harvesting De-budding & rough trimming Drying & curing Waste disposal Aphria One The 700,000 square foot Part IV Expansion and the 100,000 square foot Part V expansion represent the completion of Aphria’s five-part expansion at Aphria. Once in full rotation, Part IV and Part V will produce on an incremental annualized basis 80,000 kg bringing the total annualize production capacity at Aphria One to 110,000 kg. We Have A Good Thing Growing About Aphria Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents. For more information, visit www.aphria.ca

When Cron Breaks $30.00 CDN Then It Will Run To $35.00 See Video Reviews

Friday Summary CRON Buy The Dip... Don't Question It Just Buy It

Cronos The Stock To Buy

Cronos Group: around 120,000 kilos

You'd probably think Cronos Group (NASDAQ:CRON) is the greatest thing since sliced bread, given that it's doubled since early December. But it's only on track to be Canada's seventh largest grower by annual output. Most of Cronos Group's production will come from its joint venture known as Cronos GrowCo (70,000 kilos), with Peace Naturals kicking in 40,000 kilos at its peak. The wild card for Cronos will be how much cannabinoid production it can expect following a partnership with Ginkgo Bioworks that'll cost it up to $100 million.

https://www.fool.com/investing/2019/02/24/11-marijuana-growers-thatll-top-100000-kilograms-a.aspx

A powerful partner

There are marijuana companies that are bigger than Cronos Group by revenue and planned marijuana production. But Cronos and Canopy Growth are the only two cannabis companies with significant financial firepower and access to supply-chain, branding, and regulatory expertise because of investments from major consumer-goods companies. Cronos Group sold 45% of itselfto tobacco powerhouse Altria (NYSE: MO) for $1.8 billion in December; this followed Canopy Growth's decision to sell 38% of itself to alcohol giant Constellation Brands (NYSE: STZ) for roughly $4 billion last August.

Having Altria as a partner is a big win for Cronos Group. Altria owns the U.S. Philip Morris tobacco brands, including Marlboro cigarettes, and it has extensive experience navigating regulatory scrutiny. It's built up a slate of successful brands, and it has extensive relationships with farmers and other suppliers. Additionally, Altria owns over 30% of Juul, a leading vape company that theoretically could provide Cronos Group with some intriguing collaboration opportunities.

Cronos Group hasn't reported results for the calendar fourth quarter yet, so we don't know how it did after recreational sales began in Canada -- but sales jumped 186% year over year to CA$3.8 million in the third quarter, so its products appear to be gaining traction. Its annualized production capacity was just 6,650 kilograms in Q3, but it has said that capacity will reach 40,150 kilograms this year and that it plans to produce 117,000 kilograms per year. Those predictions were prior to Altria's investment, so you could see Cronos Group announce new targets during its next earnings release.

During Altria's fourth-quarter earnings call, it highlighted a forecast for legal marijuana sales of $40 billion per year, based on current legal markets. It also said worldwide legalization could increase that market opportunity to $250 billion. Given those figures and Altria's help, it could be smart to own Cronos Group for the long haul, too.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends Constellation Brands. The Motley Fool 

https://www.fool.com/investing/2019/02/19/3-marijuana-stocks-to-buy-for-long-haul-in-2019.aspx